VGXI Selects Cryoport for Biostorage, Bioservices and Supply Chain Solutions to Advance Next-Generation Therapies | CYRX Stock News

Cryoport, Inc. (NASDAQ: CYRX) and VGXI, Inc. have announced a strategic partnership to support biopharmaceutical companies in developing cell and gene therapies and mRNA-based treatments. The collaboration will commence in October 2024, with Cryoport Systems providing biostorage and bioservices from its Houston, Texas facility for plasmid DNA products manufactured at VGXI's facilities in The Woodlands and Conroe, Texas.

This partnership combines VGXI's expertise in plasmid DNA manufacturing with Cryoport's integrated supply chain solutions, including shipping services, data solutions, and comprehensive support services. The collaboration aims to enhance support for biopharmaceutical companies developing next-generation therapies, ensuring seamless final delivery to VGXI's end customers.

Cryoport, Inc. (NASDAQ: CYRX) e VGXI, Inc. hanno annunciato una partnership strategica per sostenere le aziende biopharmaceutical nella sviluppo di terapie cellulari e geniche e trattamenti basati su mRNA. La collaborazione avrà inizio a ottobre 2024, con Cryoport Systems che fornirà biostorage e bioservices dalla sua sede di Houston, Texas, per i prodotti di DNA plasmidico prodotti negli stabilimenti di VGXI a The Woodlands e Conroe, Texas.

Questa partnership combina l'esperienza di VGXI nella produzione di DNA plasmidico con le soluzioni integrate della catena di approvvigionamento di Cryoport, che includono servizi di spedizione, soluzioni di dati e servizi di supporto completi. L'obiettivo della collaborazione è migliorare il supporto per le aziende biopharmaceutical che sviluppano terapie di nuova generazione, garantendo una consegna finale senza intoppi ai clienti finali di VGXI.

Cryoport, Inc. (NASDAQ: CYRX) y VGXI, Inc. han anunciado una asociación estratégica para apoyar a las empresas biofarmacéuticas en el desarrollo de terapias celulares y génicas, así como tratamientos basados en mRNA. La colaboración comenzará en octubre de 2024, con Cryoport Systems proporcionando biostorage y bioservices desde su instalación en Houston, Texas, para productos de ADN plasmídico fabricados en las instalaciones de VGXI en The Woodlands y Conroe, Texas.

Esta asociación combina la experiencia de VGXI en la fabricación de ADN plasmídico con las soluciones integradas de la cadena de suministro de Cryoport, que incluyen servicios de envío, soluciones de datos y servicios de soporte completos. La colaboración tiene como objetivo mejorar el apoyo a las empresas biofarmacéuticas que desarrollan terapias de nueva generación, asegurando una entrega final sin problemas a los clientes finales de VGXI.

Cryoport, Inc. (NASDAQ: CYRX)와 VGXI, Inc.는 생명 의약품 회사들이 세포 및 유전자 치료 및 mRNA 기반 치료제를 개발할 수 있도록 지원하는 전략적 파트너십을 발표했습니다. 이 협력은 2024년 10월에 시작되며, Cryoport Systems는 텍사스 휴스턴의 시설에서 VGXI의 The Woodlands 및 Conroe, 텍사스에 있는 시설에서 제조된 플라스미드 DNA 제품을 위한 생물 저장 및 생물 서비스를 제공합니다.

이 파트너십은 VGXI의 플라스미드 DNA 제조 전문성과 Cryoport의 통합 공급망 솔루션, 즉 배송 서비스, 데이터 솔루션 및 종합 지원 서비스를 결합합니다. 이 협력의 목표는 차세대 치료제를 개발하는 생명 의약품 회사를 지원하는 데 중점을 두고, VGXI의 최종 고객에게 원활한 최종 배송을 보장하는 것입니다.

Cryoport, Inc. (NASDAQ: CYRX) et VGXI, Inc. ont annoncé un partenariat stratégique pour soutenir les entreprises biopharmaceutiques dans le développement de thérapies cellulaires et géniques et de traitements basés sur l'ARNm. La collaboration débutera en octobre 2024, avec Cryoport Systems fournissant biostorage et bioservices depuis ses installations à Houston, Texas, pour des produits d'ADN plasmidique fabriqués dans les installations de VGXI à The Woodlands et Conroe, Texas.

Ce partenariat allie l'expertise de VGXI en matière de fabrication d'ADN plasmidique aux solutions intégrées de la chaîne d'approvisionnement de Cryoport, qui incluent des services d'expédition, des solutions de données et des services de soutien complets. L'objectif de la collaboration est d'améliorer le soutien des entreprises biopharmaceutiques développant des thérapies de nouvelle génération, en garantissant une livraison finale fluide aux clients finaux de VGXI.

Cryoport, Inc. (NASDAQ: CYRX) und VGXI, Inc. haben eine strategische Partnerschaft angekündigt, um biopharmazeutischen Unternehmen bei der Entwicklung von Zell- und Gentherapien sowie mRNA-basierten Behandlungen zu unterstützen. Die Zusammenarbeit beginnt im Oktober 2024, wobei Cryoport Systems Biostorage und Bioservices von seinem Standort in Houston, Texas, für plasmid DNA Produkte bereitstellt, die in den Einrichtungen von VGXI in The Woodlands und Conroe, Texas, hergestellt werden.

Diese Partnerschaft kombiniert VGXI's Fachwissen in der Herstellung von plasmid DNA mit Cryoports integrierten Lieferkettenlösungen, einschließlich Versanddiensten, Datenlösungen und umfassenden Unterstützungsdiensten. Das Ziel der Zusammenarbeit ist es, die Unterstützung für biopharmazeutische Unternehmen, die Therapien der nächsten Generation entwickeln, zu verbessern und eine nahtlose Endlieferung an die Endkunden von VGXI zu gewährleisten.

This partnership between Cryoport and VGXI is a strategic move that could significantly enhance the development and delivery of advanced therapies. The collaboration combines VGXI's expertise in plasmid DNA manufacturing with Cryoport's supply chain solutions, creating a more streamlined process for biopharmaceutical companies.

Key points to consider:

While this partnership is promising, investors should monitor its execution and impact on Cryoport's financial performance in the coming quarters.

This strategic partnership represents a significant optimization of the biopharmaceutical supply chain. By integrating VGXI's manufacturing capabilities with Cryoport's end-to-end supply chain solutions, the collaboration addresses several critical challenges in the advanced therapy space:

The proximity of Cryoport's Houston facility to VGXI's Texas-based operations is a logistical advantage, potentially reducing transportation costs and risks. This partnership could set a new industry standard for integrated biomanufacturing and supply chain management, giving both companies a competitive edge. Investors should view this as a positive development that strengthens Cryoport's position in the life sciences logistics market.

Partnership Will Enhance Support for Biopharmaceutical Companies in Developing Cell and Gene Therapies and mRNA-Based Treatments

NASHVILLE, Tenn. and CONROE, Texas, Oct. 15, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport"), a global leader in supply chain solutions for the life sciences, and VGXI, Inc., (VXGI) a subsidiary of GeneOne Life Science Inc. ("GeneOne" KOSPI: 011000) today announced a strategic partnership to support biopharmaceutical companies in developing cell and gene therapies and mRNA-based treatments.

VGXI is a leading contract developer and manufacturer specializing in nucleic acid biopharmaceuticals, including gene therapies, DNA vaccines and RNA medicines, and ADC applications. Through this new partnership, Cryoport Systems will provide biostorage and bioservices from its Houston, Texas, facility for plasmid DNA products manufactured at VGXI's state-of-the-art facilities in The Woodlands, Texas, and its new headquarters and manufacturing location in Conroe, Texas. The collaboration brings together VGXI's industry-leading expertise in plasmid DNA manufacturing with Cryoport's fully integrated, end-to-end supply chain solutions. These include shipping services, data solutions and comprehensive support services, ensuring seamless final delivery to VGXI's end customers. Partnership operations are set to commence in October 2024.

Jerrell Shelton, CEO of Cryoport, commented, "Being chosen by VGXI as a partner for biostorage and bioservices underscores our shared commitment to quality and innovation. VGXI has a proven track record of delivering high-quality plasmid DNA for commercial gene therapies and clinical trial testing of leading treatment candidates. Together, we will provide biopharmaceutical companies a comprehensive and integrated solution to support clinical programs that are developing lifesaving, next-generation therapeutic modalities, a key part of our mission."

Young Park, CEO of VGXI, added, "We are thrilled to launch this partnership to support our client's advanced therapy programs, including cell and gene therapies, mRNA-based treatments and DNA vaccines. Choosing Cryoport as our trusted and reliable partner further elevates our mission by ensuring safe, secure, and world-class storage and transport of these assets."

About Cryoport, Inc.

Cryoport, Inc. (Nasdaq: CYRX), is a global leader in supply chain solutions for the Life Sciences with an emphasis on cell & gene therapies. Cryoport enables manufacturers, contract manufacturers (CDMO's), contract research organizations (CRO's), developers, and researchers to carry out their respective business with products and services that are designed to derisk services and provide certainty. We provide a broad array of supply chain solutions for the life sciences industry. Through our platform of critical products and solutions including advanced temperature-controlled packaging, informatics, specialized bio-logistics services, bio-storage, bio-services, and cryogenic systems, we are "Enabling the Future of Medicine™" worldwide, through our innovative systems, compliant procedures, and agile approach to superior supply chain management.

Our corporate headquarters, located in Nashville, Tennessee, is complemented by over 50 global locations in 17 countries, with key sites in the United States, United Kingdom, France, the Netherlands, Belgium, Portugal, Germany, Japan, Australia, India, and China.

For more information, visit www.cryoportinc.com or follow via LinkedIn at https://www.linkedin.com/company/cryoportinc or @cryoport on X, formerly known as Twitter at www.twitter.com/cryoport for live updates.https://myoridge.co.jp/

About VGXI, Inc.

VGXI is a leader in plasmid DNA contract manufacturing, with 20+ years of experience providing high quality products to biomedical researchers worldwide. We support clients that develop DNA vaccines, immunotherapies, cell therapies, and gene therapies. VGXI's manufacturing process and quality controls are coupled to a continuous, low-shear AIRMIX® patented lysis technology, and proprietary purification processes that provide highly supercoiled plasmid production and exceptional purity. VGXI's portfolio includes high quality plasmid for preclinical research, Highly Documented (HD) plasmid as a critical raw material for GMP viral vector production or pharm/tox studies, cGMP plasmid DNA for clinical utilization through commercial supply, and custom services. Since 2008, VGXI has been a subsidiary of GeneOne Life Science. To learn more, visit https://www.vgxii.com.

About GeneOne Life Science

GeneOne Life Science Inc. ("GeneOne" KOSPI: 011000) headquartered in Seoul, South Korea is an international biotechnology company and a leading contract manufacturer of DNA plasmids for use in vaccines, gene therapies, and cell therapies. GeneOne has recently expanded into the manufacture and development of mRNA. GeneOne has maintained a focus on vaccines against emerging infectious diseases to address global needs, including in resource challenged regions. Its small molecule portfolio of immunomodulators address diseases such as prevention of upper respiratory bacterial and viral diseases, and treatment of autoimmune and inflammatory diseases. GeneOne has three products against COVID-19 in clinical development: GLS-5310 DNA vaccine (Phase I/IIa), GLS-1200 nasal spray to prevent COVID-19 infection (Phase II), and GLS-1027 to prevent the inflammation and clinical worsening for those infected with COVID-19 (Phase II). For more information, visit https://www.genels.com.

Forward-Looking Statements

Statements in this press release which are not purely historical, including statements regarding Cryoport's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, those related to Cryoport's industry, business, long-term growth prospects, plans, strategies, acquisitions, future financial results and financial condition, such as Cryoport's outlook and updated guidance for full year 2024 revenue and the related assumptions and factors expected to drive revenue, projected growth trends in the markets in which the Cryoport operates, Cryoport's plans and expectations regarding the launch of new products and services, such as the expected timing and benefits of such products and services launches, Cryoport's expectations about future benefits of its acquisitions, and anticipated regulatory filings, approvals, label/geographic expansions or moves to earlier lines of treatment approved with respect to the products of Cryoport's clients. Forward-looking statements also include those related to Cryoport's plans and expectations relating to its recently announced cost reduction and capital realignment measures, including that such measures will be fully implemented by the end of 2024 and will positively impact Cryoport's financial results for the second half of 2024 with approximately $22 million in annualized cost savings, driving Cryoport towards its goal of profitability, as well as a return to positive adjusted EBITDA in 2025; Cryoport's expectations of continued softness in demand in its Life Sciences Products business with demand to improve over the longer term as excess freezer capacity is absorbed; Cryoport's expectations that its revenue will continue to improve progressively during the course of the remainder of 2024, along with a return to year-over-year revenue growth in the second half of 2024; Cryoport's beliefs about a broad-based market recovery for the life sciences industry except for China, which it believes will remain challenged through 2025; Cryoport's expectations of sequential improvements across its Life Sciences Services offerings driven in part by the ramp of clinical and commercial Cell & Gene therapies its currently supports, as well as anticipated new product and service launches later this year that will further diversify and enhance its revenue streams; and Cryoport's belief that operating costs and expenses, which include the start-up cost of services planned to be introduced during the fourth quarter and the first half of 2025, are expected to, as a percentage, decline as these introductions are made and ramped up. It is important to note that Cryoport's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic and geopolitical conditions, supply chain constraints, inflationary pressures, the effects of foreign currency fluctuations, trends in the products markets, variations in Cryoport's cash flow, market acceptance risks, and technical development risks. Additional risks and uncertainties include difficulties, delays or Cryoport's inability to successfully complete its planned cost reduction and capital realignment measures, which could reduce the benefits realized from such activities within the time periods currently anticipated. Cryoport's business could be affected by other factors discussed in Cryoport's SEC reports, including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC. The forward-looking statements contained in this press release speak only as of the date hereof and Cryoport cautions investors not to place undue reliance on these forward-looking statements. Except as required by law, Cryoport disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

View original content to download multimedia:https://www.prnewswire.com/news-releases/vgxi-selects-cryoport-for-biostorage-bioservices-and-supply-chain-solutions-to-advance-next-generation-therapies-302276228.html

SOURCE Cryoport, Inc.